# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2017 Earnings Results

**Report date:** 2017-08-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2017

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 2.04%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.17 | N/A | +30.59% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and future prospects. However, they did not provide specific guidance for upcoming quarters.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They emphasized ongoing investment in R&D to drive future growth.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Regeneron's earnings report showed a strong EPS performance, exceeding expectations by over 30%. Despite this positive surprise, the stock fell by 2.04% in reaction, which may indicate investor concerns about future revenue or overall market conditions. The lack of guidance could also contribute to uncertainty among investors.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2017_